Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-12-01
Based on 661 first isolates · URO · Cystitis (lower UTI) · 2023-12-03 → 2024-12-01
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (79 %–84 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Klebsiella pneumoniae (6 %), Pseudomonas aeruginosa (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
83 %
87 %
n = 46
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
76 %
n = 46
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
85 %
n = 46
ceftriaxone CRO
trend · Escherichia coli
76 %
78 %
n = 46
mecillinam MEC
trend · Escherichia coli lower UTI only
75 %
74 %
n = 46
ciprofloxacin CIP
trend · Escherichia coli
73 %
76 %
n = 46
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
70 %
n = 46
70 %
76 %
n = 46
49 %
37 %
n = 46
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
11 %
n = 46
4 %
7 %
n = 46
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
4 %
n = 46

Most likely organisms for this profile

Escherichia coli
55 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
4 %
Staphylococcus aureus
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.